10th Jul 2006 07:01
Dechra Pharmaceuticals PLC10 July 2006 Issued by Citigate Dewe Rogerson Ltd, BirminghamDate: Monday, 10 July 2006 Embargoed: 7.00am Dechra Pharmaceuticals PLC Pre-Close Period Update Dechra Pharmaceuticals PLC ("the Group") issues the following pre-close updateahead of publication of the Group's Preliminary results for the year ended 30June 2006. Product Development Update The clinical trial work required to obtain regulatory approval for Vetoryl(R)Capsules and Felimazole(R) Tablets in the USA is progressing according to plan.As previously indicated, these trials are expected to be completed prior to theend of 2007. Towards the end of our financial year, Vetoryl(R) Capsules were launched inFrance, Germany and the Benelux countries by our European Marketing Partner.Although this only had a small impact on results in the financial year ended 30June 2006, we anticipate that the contribution will be more substantial in 2007. Current Trading Trading in the second half of our financial year ended 30 June 2006 continued tobe encouraging with the Group achieving revenue growth of approximately 10.5%for the year. We continue to make solid progress across the business which is reflected in theperformance of both our Pharmaceuticals and Services Divisions and in-line withmanagement expectations. Shareholders will be updated further at the time of the Group's PreliminaryResults scheduled for 5 September 2006. Enquiries:Ian Page, Chief ExecutiveSimon Evans, Group Finance Director Fiona Tooley, DirectorDechra Pharmaceuticals PLC Citigate Dewe Rogerson LtdTel: +44 (0)1782 771100 Tel: +44 (0)121 455 8370Mobile: +44 (0)7775 642222 (IP) or +44 (0)7775 642220 (SE) Mobile: +44 (0)7785 703523www.dechra.com This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
DPH.L